DefinitionThis section has been translated automatically.
Pharmacodynamics (Effect)This section has been translated automatically.
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] inhibits IL-12 production by activated macrophages and dendritic cells, providing a new interpretation of its immunosuppressive properties. 1,25(OH)2D3 significantly inhibits mRNA expression for the IL-12 subunits p35 and p40 at the transcriptional level. There is evidence of transcriptional inhibition of the p40 gene by 1,25(OH)2D3, which required co-expression of VDR with RXR and an intact VDR DNA-binding domain. The repressive effect can be attributed to a region in the p40 promoter that contains a binding site for NF-kappaB (p40-kappaB). Activation of monocytic THP-1 cells in the presence of 1,25(OH)2D3 leads to reduced binding to the p40-kappaB site. It can be assumed that 1,25(OH)2D3 negatively regulates IL-12 production by downregulating NF-kappaB activation and binding to the p40-kappaB sequence (D'Ambrosio D et al. 1998)
You might also be interested in
IndicationThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Standard concentrationThis section has been translated automatically.
Undesirable effectsThis section has been translated automatically.
Cream/ointment: Occasional temporary itching, burning and erythema, especially in intertriginous areas. Occurrence of facial and perioral dermatitis (see also eczema, contact dermatitis, allergic dermatitis), which subside after the end of treatment. Continuous use in high doses may lead to hypercalcemia and/or increased calcium excretion in the urine.
Solution: S.o., in addition possibly worsening of psoriasis, photosensitivity, rarely hypercalcemia, hypercalciuria.
Disseminated molluscum contagiosum infections have occasionally been observed in psoriatic patients under combined calipotriol/betamethasone ointment therapy (Ji Young Ahn 2020)
InteractionsThis section has been translated automatically.
ContraindicationThis section has been translated automatically.
IncompatibilityThis section has been translated automatically.
PreparationsThis section has been translated automatically.
Daivonex® - cream, ointment, solution
Daivobet® - gel, ointment (combination with betamethasone dipropionate)
Xamiol® - gel (combination with betamethasone dipropionate)
Enstilar® - foam (spray foam galenic, also combination with betamethasone diproprionate)
Dovobet® - gel (combination with betamethasone diproprionate)
Calcipotriol - Solution
Calcipotriol Comp - Ointment
PatientinformationThis section has been translated automatically.
LiteratureThis section has been translated automatically.
- D'Ambrosio D et al. (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252-262.
- Bae JY et al. (2020) A case of disseminated molluscum contagiosum caused by topical calcipotriol/betamethasone in an immunocompetent adult. J Dtsch Dermatol Ges 18:44-46.